HQ Function

Serves as a key research and development hub, focusing on the discovery and development of T-cell therapies. Post-acquisition by AstraZeneca, it contributes to AstraZeneca's broader oncology R&D efforts, particularly in cell therapy.

Notable Features:

Located in an area with a high concentration of biotech companies and research institutions. Facilities are equipped with advanced laboratories for cellular and molecular biology research and cGMP manufacturing capabilities for engineered T-cells.

Work Culture:

As part of AstraZeneca, the work culture emphasizes scientific rigor, innovation, and collaboration, aligned with AstraZeneca's global standards. Prior to acquisition, Neogene fostered a dynamic, fast-paced startup environment focused on cutting-edge science and translational research.

HQ Significance:

This location was crucial for Neogene's European operations, R&D activities, and early manufacturing, playing a vital role in advancing its TCR-T therapy pipeline. It now represents an important cell therapy research and development site within AstraZeneca's network.

Values Reflected in HQ: The site reflects a commitment to scientific excellence, cutting-edge research, patient-centricity, and the pursuit of innovative cancer treatments, values shared by both Neogene and AstraZeneca.

Location:

Prior to its acquisition by AstraZeneca, Neogene Therapeutics operated primarily with headquarters and R&D/manufacturing facilities in Amsterdam, Netherlands, and Santa Monica, California, USA. As part of AstraZeneca, Neogene's innovative TCR-T technologies and programs are now integrated into AstraZeneca's extensive global oncology R&D and clinical operations network. This network spans across North America, Europe, Asia, and other key regions, enabling global clinical trial execution, potential for scaled-up manufacturing, and broader research collaborations worldwide.

Street Address:

Paasheuvelweg 25

City:

Amsterdam

State/Province:

North Holland

Country:

Netherlands